Sanofi (SNY) +2.5%) and its partner KaloBios Pharmaceuticals (KBIO) +5%) say the FDA has granted...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi (SNY) +2.5%) and its partner KaloBios Pharmaceuticals (KBIO) +5%) say the FDA has granted fast-track designation for the investigation of KB001A, an antibody fragment intended for protection against bacterial pneumonia caused by Pseudomonas aeruginosa in mechanically-ventilated patients. Under the partnership arrangement SNY is responsible for all clinical development, and is currently conducting a Phase I trial of the monoclonal antibody in the U.S. and has started Phase IIb planning.